Dose-response relationships for human tumors: Implications for clinical trials of dose modifying agents

doi:10.1016/0360-3016(84)90532-7

International Journal of Radiation OncologyBiologyPhysics

Volume 10, Issue 9, September 1984, Pages 1703-1707

https://doi.org/10.1016/0360-3016(84)90532-7 Get rights and content

Abstract

Clinical benefit from dose modifying agents depends upon the effectiveness of the agents and the steepness of dose response curves for the local control of human tumors by radiotherapy. We have analyzed the two prospective trials and the many retrospective analyses of clinical data from the literature to determine what dose increment is needed to increase local control from 40 to 60%. This increment ranges from 3 to >35%. Thus a dose modifying factor of at least 1.03 (to >1.35) will be necessary for clinical detection of the benefit of a new modality, even if 135 patients are included in each arm of a trial. Two dose levels in the new treatment arm would ensure that therapeutic advantage could be assessed, and would also generate prospective dose response information.

References (39)

H.K. Awwad et al.
The dose-time relationship in the radiotherapy of carcinoma of the cervix uteri: an application of the CRE formalism
Clin. Radiol.
(1979)
P. Bataini et al.
Results of radical radiotherapeutic treatment of carcinoma of the pyriform sinus
Int. J. Radiat. Oncol. Biol. Phys.
(1982)
C.N. Coleman et al.
Initial report of the Phase 1 trial of the hypoxic cell radiosensitizer SR-2508
Int. J. Radial. Oncol. Biol. Phys.
(1984)
F. Ellis
Dose, time and fractionation: A clinical hypothesis
Clin. Radiol.
(1969)
J.F. Fowler
Doses and fractionation schemes to be employed in clinical trials of high-LET radiations
J.F. Fowler et al.
A review of hypoxic cell radiosensitization in experimental tumours
Pharmac. Ther.
(1979)
A.R. Harwood et al.
T₃ glottic cancer: An analysis of dose time-volume factors
Int. J. Radiat. Oncol. Biol. Phys.
(1980)
A.R. Harwood et al.
Supraglottic laryngeal carcinoma: An analysis of dose-timevolume factors in 410 patients
Int. J. Radiat. Oncol. Biol. Phys.
(1983)
J.M. Henk et al.
Radiotherapy and hyperbaric oxygen in head and neck cancer
Lancet
(1977)
B. Maciejewski et al.
The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx
Int. J. Radiat. Oncol. Biol. Phys.
(1983)

H.C. Moench et al.

Carcinoma of the nasopharynx

Am. J Surg.

(1972)

R. Morrison

The results of treatment of cancer of the bladder—a clinical contribution to radiobiology

Clin. Radiol.

(1975)

J.T. Parsons et al.

A re-evaluation of split course technique for squamous cell carcinoma of the head and neck

Int. J. Radiat. Oncol. Biol. Phys

(1980)

C.A. Perez et al.

Carcinoma of the tonsillar fossa. Significance of dose of irradiation and volume treated in the control of the primary tumor and metastatic neck nodes

Int. J. Radiat. Oncol. Biol. Phys.

(1976)

L.J. Peters et al.

Dose-response relationship for supraglottic laryngeal carcinoma

Int. J. Radiat. Oncol. Biol. Phys.

(1983)

L.J. Peters et al.

The problem: Tumor radioresistance in clinical radiotherapy

Int. J. Radiat. Oncol. Biol. Phys.

(1982)

J.T. Roberts et al.

A Phase I study of the hypoxic cell radiosensitizer Ro 038799

Int. J. Radiat. Oncol. Biol. Phys.

(1984)

M.I. Saunders et al.

The clinical testing of Ro 03-8799—Pharmacokinetics, toxicology, tissue and tumor concentrations

Int. J. Radiat. Oncol. Biol. Phys.

(1984)

W. Van den Bogaert et al.

The different clinical presentation, behaviour and prognosis of carcinomas originating in the epilarynx and the lower supraglottis

Radiother. Oncol.

(1983)

Cited by (32)

Cyto-genotoxicity assessment of potential radioprotector, 3,3'-diselenodipropionic acid (DSePA) in Chinese Hamster Ovary (CHO) cells and human peripheral blood lymphocytes
2014, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Our previous study showed that 3,3′-diselenodipropionic acid (DSePA), a simple, stable, and water-soluble organoselenium exhibiting glutathione peroxidase (GPx)-like activity offered good radioprotection under in vitro and in vivo conditions. Herein, we investigated the anti-genotoxic effect of DSePA in model cellular systems such as Chinese Hamster Ovary (CHO) cell line and human peripheral lymphocytes after exposure to γ-radiation. The measurements on the induction of γ-H2AX foci and micronuclei frequency in the cell nuclei indicated that pretreatment with DSePA significantly prevented the radiation induced DNA damage or genotoxicity and subsequent cytotoxicity without exerting its own toxicity. The maximum protective effect of DSePA was seen at a pre-treatment concentration of 3 μg/ml. The mechanistic investigations in CHO cells revealed that DSePA pretreatment prevented the radiation induced ROS generation, lipid peroxidation and subsequent apoptosis in these cells. Further, it was seen to augment the mRNA expressions of GPx2 significantly and GPx4 marginally without causing much change in the total GPx activity after radiation exposure. These results suggested the roles of GPx2 and GPx4 in DSePA mediated radioprotection. In conclusion our results confirm the nongenotoxic nature of the DSePA and validate its radioprotective efficacy and mechanisms of action in model cellular systems.
Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate
2001, International Journal of Radiation Oncology Biology Physics
Purpose: To use portal imaging to measure daily on-line setup error and off-line prostatic motion in patients treated with conformal radiotherapy to determine an optimum planning target volume (PTV) margin incorporating both setup error and organ motion.
Results: A total of 2549 portal images from 33 patients were acquired over the course of the study. Of these patients, 23 were analyzed for setup errors while the remaining 10 were analyzed for prostatic motion. Setup errors were characterized by standard deviations of 1.8 mm in the anterior-posterior (AP) direction and 1.4 mm in the superior-inferior (SI) direction. Displacements due to prostatic motion, with standard deviations of 5.8 mm AP and 3.3 mm SI, were found to be more significant than setup errors.
Conclusions: Taking into account both setup errors and target organ motion, optimum PTV margins to ensure 95% coverage are 10.0 mm AP and 5.9 mm SI. The portal imaging protocol established in this study allows radiation therapists to accept or adjust a treatment setup based upon daily on-line image matching results. The successful localization of radiopaque fiducial markers on a significant number of portal images acquired in the study gives hope that more accurate on-line targeting verification may soon be possible through the visualization of the prostate itself as opposed to the surrounding bony structures of the pelvis.
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial
1999, Lancet
Radical radiotherapy is commonly used to treat localised prostate cancer. Late chronic side-effects limit the dose that can be given, and may be linked to the volume of normal tissues irradiated. Conformal radiotherapy allows a smaller amount of rectum and bladder to be treated, by shaping the high-dose volume to the prostate. We assessed the ability of this new technology to lessen the risk of radiation-related effects in a randomised controlled trial of conformal versus conventional radiotherapy.
We recruited men with prostate cancer for treatment with a standard dose of 64 Gy in daily 2 Gy fractions. The men were randomly assigned conformal or conventional radiotherapy treatment. The primary endpoint was the development of late radiation complications (>3 months after treatment) measured with the Radiation Therapy and Oncology Group (RTOG) score. Indicators of disease (cancer) control were also recorded.
In the 225 men treated, significantly fewer men developed radiation-induced proctitis and bleeding in the conformal group than in the conventional group (37 vs 56% ≥RTOG grade 1, p=0·004; 5 vs 15% ≥RTOG grade 2, p=0·01). There were no differences between groups in bladder function after treatment (53 vs 59% ≥grade 1, p=0·34; 20 vs 23% ≥grade 2, p=0·61). After median follow-up of 3·6 years there was no significant difference between groups in local tumour control (conformal 78% [95% CI 66–86], conventional 83% [69–90]).
Conformal techniques significantly lowered the risk of late radiation-induced proctitis after radiotherapy for prostate cancer. Widespread introduction of these radiotherapy treatment methods is appropriate. Our results are the basis for dose-escalation studies to improve local tumour control.
The accuracy of patient positioning in rectum cancer irradiation
1998, Cancer/Radiotherapie
Évaluation du système d'imagerie Portalvision lors des irradiations pelviennes.
Treize patients atteints d'un cancer du rectum ont participé à cette étude. Treize films de simulation et 208 images de contrôle de haute énergie ont été réalisés. Les patients ont été traités par trois faisceaux. Seul le faisceau postérieur a été analysé, la qualité des images de contrôle de haute énergie des faisceaux latéraux étant insuffisante. Pour les champs latéraux, des photons de 25 MV ont été utilisés, pour le champ postérieur, des photons de 6 MV. Après la première mise en place correcte validée, aucune correction n'a été réalisée pendant toute la durée de l'irradiation. Les variations de mise en place dans le sens des X (droite-gauche), des Z (tête-pied), ainsi que la rotation dans le plan frontal ont été mesurées.
Les variations moyennes, les écarts-types, et leurs fréquences cumulatives respectives ont été déterminés pour chaque paramètre. Les variations moyennes (différence entre les mesures sur l'image de simulation et sur les images de contrôle de haute énergie suivantes) étaient respectivement de 3,2 mm, 0,9 mm et 3,6 mm pour X, Z et la rotation dans le plan frontal. Les écarts-types étaient respectivement de 7,1 mm, 7,1 mm et 1,5 mm. Quatrevingts pour cent des champs d'irradiation ont été mis en place avec une erreur de positionnement inférieure à 10 mm, et 95 % avec une erreur inférieure à 17,5 mm.
Les variations parfois importantes des paramètres mesurés incitent à proposer l'utilisation hebdomadaire d'un système d'imagerie de contrôle électronique et la mise en place de systèmes de contention.
To evaluate a ionization chamber on-line portal imaging system in routine clinical radiotherapy of rectum cancers.
Megavolt portal images were obtained using a fast electronic megavoltage radiotherapy imaging system in 13 cases of pelvic fields. A total of 208 portal images and 13 simulator films were used to determine the values of set-up deviations in the X-Z directions of a fixed co-ordinate system, and of the rotation fields (R).
Mean standard deviations of the difference between simulation and treatment images were 3.2 mm and 0.9 mm for X and Z, 3.6 mm for the rotation fault. The standard deviations were, respectively, 7.1 mm, 7.1 mm and 1.5 mm. The cumulative frequency distributions revealed that 80% and 95% of the absolute differences were less than 10 mm and 17.5 mm, respectively.
These results indicate the difficulty of a reproducible daily set-up. A weekly control could be proposed in order to increase the quality of pelvic site treatment. The introduction of masks to improve the set-up is also discussed.
Normal tissue radiosensitivity - how important is it?
1996, Clinical Oncology
The success of radiotherapy in eradicating tumours depends on the total radiation dose, but what limits this dose is the tolerance of the normal tissues within the treatment volume. Selection of the appropriate dose for all patients is based on a balance between minimising the incidence of severe normal tissue complications and maximizing the probability of local control. In patients treated to the same radical dose, a wide range of reactions is seen; in many clinical situations, radical doses are limited by the minority of patients whose normal tissues are particularly sensitive. Clinical studies of radiotherapy reactions have demonstrated that a large part of the spectrum of normal tissue reactions, perhaps as much as 80%, is due to differences in individual normal tissue sensitivity. This suggests that it might be possible to measure this sensitivity and to change treatment accordingly. The main objective of normal tissue sensitivity testing is to permit dose escalation without increased normal tissue complication rates in patients with more resistant normal tissues. Calculations suggest that the most ‘resistant’ 40% of patients could be dose escalated by 17%–18% which is likely to be associated with significant gains in local control, perhaps by as much as 34%–36%; this should translate into an increase in overall survival. It should also be possible to identify those relatively few patients who suffer serious normal tissue morbidity with conventional doses. Thus, if successful, predictive testing of normal tissue response should improve the therapeutic ratio of radiotherapy.
Radiation dose-response of human tumors
1995, International Journal of Radiation Oncology, Biology, Physics

View all citing articles on Scopus

^☆: Proceedings of Banff Conference on: Chemical modifiers of Cancer Treatment.

View full text

Dose-response relationships for human tumors: Implications for clinical trials of dose modifying agents☆

Abstract

Clin. Radiol.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radial. Oncol. Biol. Phys.

Clin. Radiol.

Pharmac. Ther.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Lancet

Int. J. Radiat. Oncol. Biol. Phys.

Am. J Surg.

Clin. Radiol.

Int. J. Radiat. Oncol. Biol. Phys

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Int. J. Radiat. Oncol. Biol. Phys.

Radiother. Oncol.